Study: Drug, chemo combo double survival in metastatic lung cancer | RSS News Feed

Study: Drug, chemo combo double survival in metastatic lung cancer - Latest News

RSS Feed for this news: Study: Drug, chemo combo double survival in metastatic lung cancer

Study: Drug, chemo combo double survival in metastatic lung cancer

April 17 (UPI) --Combining the immunotherapy drug pembrolizumab with chemotherapy doubled survival in patients with some forms of lung cancer compared with chemo alone, according to an international Phase III clinical trial. Researchers found the promising ... read more

Treatment combo nearly doubles survival time in lung cancer patients, study finds

Pembrolizumab, sold under the brand name Keytruda, is an FDA-approved drug sold by a subsidiary of Merck & Company, Inc. that sponsored this study ... cancer — and improving the overall survival of patients with metastatic lung cancer compared to ... read more

Combination therapy doubles survival in metastatic lung cancer

The immunotherapy drug pembrolizumab ... this study may suggest a new standard of care." NYU Langone Health / NYU School of Medicine. (2018, April 16). Combination therapy doubles survival in metastatic lung cancer: Pembrolizumab and chemotherapy in ... read more

Looking for another news?


Treatment combo improves lung cancer survival times, study finds

Pembrolizumab, sold under the brand name Keytruda, is an FDA-approved drug sold by a subsidiary of Merck & Company, Inc. that sponsored this study ... cancer -- and improving the overall survival of patients with metastatic lung cancer compared to ... read more

Combination of Pembrolizumab and Chemotherapy Doubles Survival in Patients with Metastatic Lung Cancer

Newswise — The immunotherapy drug pembrolizumab, when combined with chemotherapy, doubles survival ... combination treatment (5.2% vs. 0.5%). The most common side effects experienced by both groups were nausea, anemia and fatigue. Non-small cell lung ... read more

Immunotherapy improves statistics of survival in lung cancer patients

In the latest study called “Pembrolizumab plus Chemotherapy in Metastatic Non–Small-Cell Lung Cancer ... overall survival and progression-free survival. However, adverse effects occurred in 67.25 of the patients in the pembrolizumab-combination ... read more

Merck's Keytruda Betters Survival in Lung Cancer Combo Study

The study evaluated the combination therapy for first-line treatment of patients with metastatic non-squamous non-small cell lung cancer ... drug Opdivo for NSCLC. However, Merck’s Keytruda combination demonstrated better overall survival compared ... read more

Study: Combination therapy nearly doubles lung cancer survival time

Compared to patients treated only with chemotherapy, the combination of an immunotherapy drug and chemotherapy almost doubled the survival time for some lung cancer patients, according to a study published ... of patients with metastatic lung cancer ... read more

Adding Merck's Keytruda To Chemo Halves Death Risk For Lung Cancer Patients

“If you have metastatic lung cancer and there ... trial could read out survival results of the Opdivo-Yervoy combo based on PD-L1 later this year. Immunotherapy drugs can tend to show their survival benefits later than chemotherapy, as it takes time ... read more

Long-Term Atezolizumab Findings Confirm Long-Term Survival Exists in Lung Cancer, Expert Says

According to 3-year survival findings from the phase II POPLAR study, anti PD-L1 immunotherapy with atezolizumab (Tecentriq) demonstrated strong superiority to docetaxel in locally advanced or metastatic non–small cell lung cancer (NSCLC). The results ... read more


FeedsRSS Created by. Full RSS Feed | Privacy Policy | Contact Us